BMS’ Deucravacitinib Fails to Meet its Primary and Secondary Endpoints in P-II LATTICE-UC Study for the Treatment of Moderate to Severe Ulcerative Colitis

Shots:

• The P-II LATTICE-UC study evaluates the safety and efficacy of deucravacitinib (PO) vs PBO in patients with mod. to sev. UC
• The trial did not meet the 1EPs of clinical remission @12wks. & 2EPs of clinical response as assessed by modified Mayo score, endoscopic response & histological improvement @12wks. The safety profile was consistent with previously reported studies in psoriasis and PsA and no new safety signals were identified
• The therapy is currently being evaluated in the P-II IM011-127 trial for the same indication. The trial also includes a higher dose. Deucravacitinib (TYK2 inhibitor) is being studied in multiple immune-mediated diseases, including psoriasis, PsA, lupus, and IBD

Click here to read full press release/ article | Ref: Businesswire | Image: BMS